COVID-19 therapeutics
Clinical Microbiology Reviews,
Journal Year:
2024,
Volume and Issue:
37(2)
Published: May 21, 2024
SUMMARYSince
the
emergence
of
COVID-19
in
2020,
an
unprecedented
range
therapeutic
options
has
been
studied
and
deployed.
Healthcare
providers
have
multiple
treatment
approaches
to
choose
from,
but
efficacy
those
often
remains
controversial
or
compromised
by
viral
evolution.
Uncertainties
still
persist
regarding
best
therapies
for
high-risk
patients,
drug
pipeline
is
suffering
fatigue
shortage
funding.
In
this
article,
we
review
antiviral
activity,
mechanism
action,
pharmacokinetics,
safety
therapies.
Additionally,
summarize
evidence
from
randomized
controlled
trials
on
various
antivirals
discuss
unmet
needs
which
should
be
addressed.
Language: Английский
Real-World Effectiveness of Sotrovimab in Ambulatory Patients With COVID-19: A Retrospective Cohort Study Using a Large Administrative Claims Database in the United States
Clinical Therapeutics,
Journal Year:
2025,
Volume and Issue:
unknown
Published: Feb. 1, 2025
Language: Английский
Real-world effectiveness of sotrovimab for the treatment of SARS-CoV-2 infection during Omicron BA.2 and BA.5 subvariant predominance: a systematic literature review
Infection,
Journal Year:
2024,
Volume and Issue:
52(5), P. 1839 - 1861
Published: April 11, 2024
To
evaluate
clinical
outcomes
associated
with
sotrovimab
use
during
Omicron
BA.2
and
BA.5
predominance.
Language: Английский
Real‐World Effectiveness of Sotrovimab in Patients Infected With SARS‐CoV‐2 Omicron Subvariant BA.2 in Western Sydney, Australia
Eric Kalo,
No information about this author
Ziad Basyouni,
No information about this author
Gizelda Katz
No information about this author
et al.
Journal of Medical Virology,
Journal Year:
2025,
Volume and Issue:
97(2)
Published: Feb. 1, 2025
ABSTRACT
Laboratory‐based
findings
suggest
that
Sotrovimab
is
significantly
less
effective
against
emerging
CARS‐CoV‐2
variants,
however,
clinical
data
lacking.
Here
we
examined
the
effectiveness
of
sotrovimab,
in
preventing
emergency
department
(ED)
presentation
and
subsequent
hospitalization
high‐risk
subgroups
patients
during
SARS‐CoV‐2
Delta
Omicron
waves
Western
Sydney,
Australia
(
n
=
515).
Risk
for
ED
attendance
was
comparable
patients,
whether
BA.1
or
BA.2,
compared
to
(hazard
ratio
0.97
[0.36–2.64]).
These
highlight
need
caution
when
using
vitro
drive
practice,
especially
consequence
withhold
potentially
lifesaving
treatment.
Language: Английский
Impact of treatment of COVID-19 with sotrovimab on post-acute sequelae of COVID-19 (PASC): an analysis of National COVID Cohort Collaborative (N3C) data
Myriam Gharbi,
No information about this author
Rose Chang,
No information about this author
Tracy Guo
No information about this author
et al.
Infection,
Journal Year:
2025,
Volume and Issue:
unknown
Published: March 22, 2025
Abstract
Purpose
To
assess
the
impact
of
early
sotrovimab
treatment
versus
no
on
risk
developing
post-acute
sequelae
COVID-19
(PASC;
long
COVID)
in
patients
(age
≥
12
years)
with
at
high
for
progression
to
severe
disease.
Methods
Retrospective
cohort
study
using
US
National
COVID
Cohort
Collaborative
(N3C)
data.
Phase
1
identified
and
assessed
multiple
definitions
PASC;
2
evaluated
effectiveness
reducing
PASC,
utilizing
from
1.
Average
effect
treated
(ATT)-weighted
Cox
proportional
hazards
regression
models
were
used
compare
time
event
PASC
between
high-risk
who
received
May
26,
2021
April
5,
2022,
diagnosed
March
2022
did
not
receive
any
during
acute
phase
or
pre-exposure
prophylaxis
against
SARS-CoV-2.
Results
A
total
9,504
sotrovimab-treated
619,668
untreated
included
main
analysis.
Most
baseline
characteristics
balanced
two
cohorts
after
ATT
weighting.
The
doubly
robust
ATT-weighted
hazard
ratio
(95%
confidence
interval)
was
0.92
(0.89–0.96)
(
p
<
0.001),
indicating
that
use
associated
a
significantly
lower
PASC.
remained
consistent
sensitivity
analyses.
Conclusion
In
COVID-19,
benefits
may
extend
beyond
contribute
prevention
symptoms.
Language: Английский
Characteristics and outcomes of patients with COVID-19 at high risk of disease progression receiving sotrovimab, oral antivirals, or no treatment: a retrospective cohort study
Myriam Drysdale,
No information about this author
Holly Tibble,
No information about this author
Vishal Patel
No information about this author
et al.
BMC Infectious Diseases,
Journal Year:
2024,
Volume and Issue:
24(1)
Published: July 4, 2024
The
clinical
benefit
of
coronavirus
disease
2019
(COVID-19)
treatments
against
new
circulating
variants
remains
unclear.
We
sought
to
describe
characteristics
and
outcomes
highest
risk
patients
with
COVID-19
receiving
early
in
Scotland.
Language: Английский
Real-World Effectiveness of Sotrovimab for the Early Treatment of COVID-19: Evidence from the US National COVID Cohort Collaborative (N3C)
Clinical Drug Investigation,
Journal Year:
2024,
Volume and Issue:
44(3), P. 183 - 198
Published: Feb. 20, 2024
The
coronavirus
disease
2019
(COVID-19)
pandemic
has
been
an
unprecedented
healthcare
crisis,
one
that
threatened
to
overwhelm
health
systems
and
prompted
urgent
need
for
early
treatment
options
patients
with
mild-to-moderate
COVID-19
at
high
risk
progression
severe
disease.
Randomised
clinical
trials
established
the
safety
efficacy
of
monoclonal
antibodies
(mAbs)
in
pandemic;
vitro
data
subsequently
led
use
mAbs
being
discontinued,
without
clear
evidence
on
how
these
were
linked
outcomes.
In
this
study,
we
describe
compare
real-world
outcomes
treated
sotrovimab
versus
untreated
patients.
Language: Английский